GSK discontinues development of the P2X3 receptor antagonist camlipixant for chronic cough

UK-based GSK discontinued development of the P2X3 receptor antagonist camlipixant for refractory chronic cough. It announced the latest information on the Phase 3 CALM-1 and CALM-2 trials on 17 July 2026.

Read in fullFrom the source, not the headline

sources corroborateOutlets reporting the same event

companies linkedAcross 0 themes, second pass

The story

UK-based GSK discontinued development of the P2X3 receptor antagonist camlipixant for refractory chronic cough. RCC was identified as the target disease, and the status of the Phase 3 CALM-1 and CALM-2 trials was announced.

The announcement date was 17 July 2026, and the latest information on the efficacy, safety and tolerability of the trials was made public.

At a glance

CompanyUK-based GSK discontinued development of camlipixant

Drug namecamlipixant

ApplicationRefractory chronic cough (RCC)

TestingPhase 3 trials of CALM-1 and CALM-2

TimingAnnouncement date: 17 July 2026

Reference information. Every claim resolves to something the story actually named.

Where this came from

We read each source in full and checked they agree on the core claim.

1/ 1 agree

All of them report the same thing.

bio.nikkeibp.co.jpNews

PrimaryOpen

Read the original articleGo to the source page

Reference information generated from public sources. It does not solicit or advise on investments. Prices are 15-minute delayed.